Alberico L. Catapano was born in Milano in 1952. He received his degree from the
University of Milano in 1975 and a specialization in Clinical Pharmacology in 1979. From 1972 he has been involved in the field of Atherosclerosis, Lipids, Lipoproteins and genetic dyslipidaemias. From the scientific standpoint Prof. Catapano has made landmark observations regarding the role of HSP’s and of Petranxins in Atherogenesis and on the role of HDL in the modulation of the immune response.

Alberico L. Catapano is Full Professor of Pharmacology at the University of Milano, Director of the Laboratory for the study of Lipoproteins and Atherosclerosis and of the Center for the Study of Atherosclerosis of the Italian Society of Atherosclerosis (S.I.S.A.) at the “Bassini” Hospital. He is also the Director of Center of Epidemiology and Preventive Pharmacology of the University of Milano (SEFAP).

Professor Catapano is Past President of the European Atherosclerosis Society (EAS), the Chairman of EAS Educational, Guidelines & Corporate Activities Committees and the Chairman of the EAS/ESC guidelines for the treatment of dyslipoproteinemias. He holds board positions in several learned Scientific Societies including the Italian Society for the Study of Atherosclerosis; he is also President of the Italian Society of Clinical and Experimental Therapy (SITeCS) and General Director of the SISA Foundation.

He has authored more than 400 scientific papers in peer reviewed journals and of several books in the area of the Atherosclerosis, Lipoproteins and Lipid Metabolism. He is the editor of Atherosclerosis Supplements and also co editor of “Atherosclerosis” and associate editor of other scientific journals.

Dr. Pablo Corral is an Internal Medicine physician and Lipidologist. He is head of the Lipids and Atherosclerosis area of the ICM Institute, Buenos Aires, Argentina. He is also a professor at the School of Medicine, Department of Pharmacology, FASTA University, Mar del Plata. Currently, he is the elected president of the Argentine Society of Lipids and a full member of the Argentine Society of Cardiology.

His research interests focus on lipid metabolism, pharmacologic innovation, and prevention of cardiovascular disease, including Familial Hypercholesterolemia, and genetics. He is the national lead investigator of the FHSC (Familial Hypercholesterolemia Studies Collaboration). He has multiple publications in these areas and presentations at local and international congresses related to atherosclerosis and lipids. In particular, he is a member of the IberoAmerican FH Network collaboration, as well as several expert societies, including the European Atherosclerosis Society (EAS) and the International Atherosclerosis Society (IAS).

El Dr. Pablo Corral es médico de Medicina Interna y Lipidólogo. Es responsable del área de Lípidos y Aterosclerosis del Instituto ICM, Buenos Aires, Argentina. También es profesor de la Facultad de Medicina, Departamento de Farmacología, Universidad FASTA, Mar del Plata. Actualmente, es el presidente electo de la Sociedad Argentina de Lípidos y miembro titular de la Sociedad Argentina de Cardiología.

Sus intereses de investigación se centran en el metabolismo de los lípidos, la innovación farmacológica y la prevención de enfermedades cardiovasculares, incluida la hipercolesterolemia familiar y la genética. Es el investigador principal nacional de la FHSC (Colaboración del estudio de Hipercolesterolemia Familiar). Tiene múltiples publicaciones en estas áreas y presentaciones en congresos locales e internacionales relacionados con la aterosclerosis y los lípidos. En particular, es miembro de la colaboración IberoAmerican FH Network, así como de varias sociedades de expertos, entre ellas la European Atherosclerosis Society (EAS) y la International Atherosclerosis Society (IAS).

BSc(hons), MBChB, MD, MPhil (Cantab), FRCP (Lon), FRCP (Ed), FACC, FESC, FAHA

Kausik Ray is Professor of Public Health at the School of Public Health, the Director of the Imperial Centre for Cardiovascular Diseas Prevention and the Deputy Director of the Imperial Clinical Trial Unit, Imperial College London and a Consultant Cardiologist.

Professor Ray received his medical education (MBChB) at the University of Birmingham, his MD at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and an MPhil in epidemiology from the University of Cambridge.

Professor Ray’s research interests focus on preventing the global consequences of atherosclerosis through large-scale population studies evaluating the burden of disease and improving risk prediction and through the study of novel therapies in the setting of multi-centre international clinical trials to offer solutions to help prevent death and disability from cardiovascular disease. As such, he is the global PI of several ongoing Cardiovascular trials and registries.

His publications are included in the NEJM, Lancet, JAMA, Circulation, JACC and EHJ amongst others and have received over 54,000 citations (2019 H index of 68, i10 of 159) and in 2018 he was listed by Clarivate Analytics as among the top 1% of authors cited globally in clinical medicine.

The impact of his novel research findings has contributed to current US and European guidelines amongst others.

An active member of the EAS, Professor Ray has contributed to more than 6 EAS Consensus Panel statements, been an invited speaker at the EAS annual congress for several years, was an EAS program committee member for 2015 (Glasgow) and 2017 (Prague) as well as his ongoing contributions to masterclasses and other EAS educational activities. Since 2017 he has served on the EAS Executive committee.

In 2014 he independently initiated and obtained funding for the EAS FH studies collaboration, the first global registry of its kind, now encompassing over 68 countries and approximately 60,000 cases, for which he is the lead.

Prof Ray has worked extensively to extend the EAS mission across Europe, the Asia Pacific, Gulf region and Latin America through education and collaborations.